145 related articles for article (PubMed ID: 37260183)
1. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM; Valdivia C; Santos M; Lanillos J; Maroto P; Anguera G; Calsina B; Martinez-Montes A; Monteagudo M; Mellid S; Leandro-García LJ; Montero-Conde C; Cascón A; Roncador G; Coloma J; Robledo M; Rodriguez-Antona C
Int J Cancer; 2023 Sep; 153(6):1300-1312. PubMed ID: 37260183
[TBL] [Abstract][Full Text] [Related]
2. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
3. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR).
Agrawal P; Chen YT; Schilling B; Gibson BW; Hughes RE
J Biol Chem; 2012 Jun; 287(25):21164-75. PubMed ID: 22544753
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
6. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J; Pham CG; Albanese SK; Dong Y; Oyama T; Lee CH; Rodrik-Outmezguine V; Yao Z; Han S; Chen D; Parton DL; Chodera JD; Rosen N; Cheng EH; Hsieh JJ
J Clin Invest; 2016 Sep; 126(9):3526-40. PubMed ID: 27482884
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
8. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
9. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
10. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
Yang J; Butti R; Cohn S; Toffessi-Tcheuyap V; Mal A; Nguyen M; Stevens C; Christie A; Mishra A; Ma Y; Kim J; Abraham R; Kapur P; Hammer RE; Brugarolas J
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2310793121. PubMed ID: 38861592
[TBL] [Abstract][Full Text] [Related]
11. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
Nakayama Y; Enomoto D; Yamamoto K; Takara K
Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines.
Nanayakkara DM; Nguyen MN; Wood SA
Cell Prolif; 2016 Aug; 49(4):494-502. PubMed ID: 27374971
[TBL] [Abstract][Full Text] [Related]
14. Biallelic
Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
17. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Santoni M; Pantano F; Amantini C; Nabissi M; Conti A; Burattini L; Zoccoli A; Berardi R; Santoni G; Tonini G; Santini D; Cascinu S
Biochim Biophys Acta; 2014 Apr; 1845(2):221-31. PubMed ID: 24480319
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
20. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
Lu Q; Zhang FL; Lu DY; Shao ZM; Li DQ
Cancer Med; 2019 Nov; 8(15):6730-6740. PubMed ID: 31512408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]